Key result
Periconceptional GLP-1 RA exposure is not linked to major adverse pregnancy outcomes but ~23% more renal malformations.
Why the study?
The association between periconceptional exposure to glucagon-like peptide-1 receptor agonists and fetal, pregnancy-related, obstetric, and delivery outcomes needed evaluation.
Does periconceptional exposure to glucagon-like peptide-1 receptor agonists increase adverse fetal, pregnancy, obstetric, and delivery outcomes in human pregnancies?
Meta-Analysis (n=49,395)
Does periconceptional exposure to glucagon-like peptide-1 receptor agonists increase adverse fetal, pregnancy, obstetric, and delivery outcomes in human pregnancies?
Current evidence does not show a consistent association between periconceptional GLP-1 receptor agonist exposure and major adverse pregnancy outcomes, providing cautious reassurance for inadvertent exposure.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for periconceptional GLP-1RA use; leaves open causal link to fetal renal malformations in low-certainty cohort data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hakim et al. (2026) conducted a meta-analysis in Pregnancy (n=49,395). Glucagon-like peptide-1 receptor agonists vs. Unexposed comparator groups was evaluated on Fetal, pregnancy-related, obstetric, and delivery outcomes (including renal malformations) (OR 1.23, 95% CI 1.09-1.39). Periconceptional GLP-1 receptor agonist exposure was not associated with major adverse pregnancy outcomes, but showed a small risk for renal malformations (OR 1.23; 95% CI 1.09-1.39).
Synapse has enriched 10 related papers. Consider them for comparative context: